NASDAQ:XENE

Xenon Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy XENE

*Your capital is at risk

$53.46

+1.16 (+2.22%)

At Close: Jun 03, 2026

Xenon Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -60.52. In total, the insiders bought 2.47M and sold 412.02K XENE shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-60.52
● Buy	2.47M shares
● Sell	412.02K shares
75% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Mar 09, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -60.52. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 05, 2025 Buy	Share Option (Right to Buy) A-Award	Garofalo Elizabeth A. Director	Director	17 012 Value: $522.8K
Jun 05, 2025 Buy	Restricted Share Units A-Award	Garofalo Elizabeth A. Director	Director	2 645 Value: $81.3K
Jun 05, 2025 Buy	Share Option (Right to Buy) A-Award	Gannon Steven Director	Director	17 012 Value: $522.8K
Jun 05, 2025 Sell	Common Shares S-Sale	Gannon Steven Director	Director	3 Value: $91
Jun 05, 2025 Buy	Restricted Share Units A-Award	Gannon Steven Director	Director	2 645 Value: $81.3K
Jun 05, 2025 Buy	Share Option (Right to Buy) A-Award	Cannon Gillian Director	Director	17 012 Value: $522.8K
Jun 05, 2025 Buy	Restricted Share Units A-Award	Cannon Gillian Director	Director	2 645 Value: $81.3K
Jun 05, 2025 Buy	Share Option (Right to Buy) A-Award	Svoronos Dawn Director	Director	17 012 Value: $522.8K
Jun 05, 2025 Buy	Restricted Share Units A-Award	Svoronos Dawn Director	Director	2 645 Value: $81.3K
Jun 05, 2025 Buy	Restricted Share Units A-Award	Svoronos Dawn Director	Director	2 645 Value: $81.3K
Jun 05, 2025 Buy	Share Option (Right to Buy) A-Award	Svoronos Dawn Director	Director	17 012 Value: $522.8K
Jun 05, 2025 Buy	Restricted Share Units A-Award	Cannon Gillian Director	Director	2 645 Value: $81.3K
Jun 05, 2025 Buy	Share Option (Right to Buy) A-Award	Cannon Gillian Director	Director	17 012 Value: $522.8K
Jun 05, 2025 Buy	Restricted Share Units A-Award	Gannon Steven Director	Director	2 645 Value: $81.3K
Jun 05, 2025 Sell	Common Shares S-Sale	Gannon Steven Director	Director	3 Value: $91
Jun 05, 2025 Buy	Share Option (Right to Buy) A-Award	Gannon Steven Director	Director	17 012 Value: $522.8K
Jun 05, 2025 Buy	Restricted Share Units A-Award	Garofalo Elizabeth A. Director	Director	2 645 Value: $81.3K
Jun 05, 2025 Buy	Share Option (Right to Buy) A-Award	Garofalo Elizabeth A. Director	Director	17 012 Value: $522.8K
Jun 05, 2025 Buy	Restricted Share Units A-Award	Gover Justin D. Director	Director	2 645 Value: $81.3K
Jun 05, 2025 Buy	Share Option (Right to Buy) A-Award	Gover Justin D. Director	Director	17 012 Value: $522.8K
Jun 05, 2025 Buy	Restricted Share Units A-Award	Machado Patrick Director	Director	2 645 Value: $81.3K
Jun 05, 2025 Buy	Share Option (Right to Buy) A-Award	Machado Patrick Director	Director	17 012 Value: $522.8K
Jun 05, 2025 Buy	Restricted Share Units A-Award	Patou Gary Director	Director	2 645 Value: $81.3K
Jun 05, 2025 Buy	Share Option (Right to Buy) A-Award	Patou Gary Director	Director	17 012 Value: $522.8K
May 14, 2025 Buy	Common Shares M-Exempt	Gannon Steven Director	Director	5 144 Value: $64.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT XENON PHARMACEUTICALS INC.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment o...

Read Full Profile Here